Browse Articles
Discover research articles across all indexed journals
Author Correction: Validation of a blood biomarker panel for machine learning-based radiation biodosimetry in juvenile and adult C57BL/6 mice
Investigation of ferroptosis and mTOR signaling in chromophobe renal cell carcinoma (ChRCC).
583 Background: ChRCC is a rare form of kidney cancer that has shown limited response to immune checkpoint inhibitors currently used as the standard-of-care for other RCC histologies. mTOR inhibition is a therapeutic strategy for advanced ChRCC, but the mechanistic basis for response remains poorly understood. We investigated clinical responses to mTOR inhibitors in patients with ChRCC and explored the underlying mechanism of therapeutic response at single-cell resolution. Methods: Clinical data from the International Metastatic RCC Database Consortium (IMDC) was used to evaluate survival outcomes, including progression-free survival (PFS) and overall survival (OS), in patients with metastatic ChRCC compared to metastatic clear cell RCC (mccRCC) treated with first-line mTOR inhibitors. To uncover the mechanisms underlying ChRCC’s clinical response and identify future therapeutic targets, we compared gene expression in ChRCC tumor cells against their cell-of-origin via scRNA-seq analysis. Epithelial cells from matched normal kidney samples were clustered and annotated into distinct known cellular types of the healthy human kidney. A logistic regression model (Young M.D. et al., 2018) was trained on normal epithelial clusters, using a set of 74 marker genes. The model was tested on ChRCC tumors to identify their cellular origin by finding the highest predicted probabilities of similarity between normal epithelial cellular types and tumor cells. Validation analysis was conducted using a separate training set (KPMP Atlas). Differential gene expression and pathway analyses between ChRCC and its cell-of-origin were then conducted. Results: Patients with metastatic ChRCC exhibited higher overall survival (OS) compared to those with metastatic clear cell RCC when treated with first-line mTOR inhibitors (median OS: 41.3 months [95% CI: 14.4-NR] vs. 13.4 months [95% CI: 10.9-15.3], respectively). After quality control, 7,425 cells from ChRCC tumors and 784 epithelial cells from adjacent normal kidney tissue were isolated for scRNA-seq analysis. Normal epithelial cells were classified into proximal tubule, loop of Henle – distal tubule, principal cells, α-intercalated cells (ICA), and β-intercalated cells (ICB). The ChRCC tumor cells showed the highest similarity to ICA cells (0.60 probability), which was confirmed in the validation analysis. Among the most upregulated genes in ChRCC compared to ICA were NUPR1, FTL, and FTH1, all associated with the inhibition of ferroptosis. The top enriched pathways included NFE2L2 signaling, ferroptosis, and mTORC1 signaling. Conclusions: Metastatic ChRCC patients demonstrate improved overall survival compared to mccRCC patients when treated with mTOR inhibitors as first-line therapy. ChRCC appears to originate from ICA cells of the normal kidney. Potential therapeutic targets in ChRCC include ferroptosis and mTOR signaling pathways.
Prospective analysis of AR-V7 expression in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) sequentially treated with docetaxel and enzalutamide.
250 Background: Androgen receptor splice variant 7 (AR-V7) has been associated with poor outcomes in mCRPC patients treated with androgen receptor pathway inhibitors (ARPI). However, its predictive value is still not clear. Methods: We conducted a prospective single-arm trial to evaluate the role of AR-V7 as a potential predictive biomarker for ARPI treatment. Patients were initially treated IV with docetaxel 75 mg/m2. Enzalutamide 160 mg daily PO was started upon progression. Blood samples were harvested before docetaxel (C1), before enzalutamide (C2), and at the time of progression on enzalutamide (C3). Outcomes analyzed included PSA50 response (decline of 50% or more from baseline), PSA Progression-free Survival (PFS), and Overall Survival (OS) from the start of treatment. AR-V7 expression in circulating tumor cells was detected using AdnaTest Prostate Cancer Detect kit (Qiagen). Results: From October 2019 to July 2021, 30 patients were included. AR-V7 expression was detected in 40% of patients at C1, 46% at C2, and 74% at C3. All four patients who became AR-V7 positive at C2 responded to enzalutamide. The PSA50 to docetaxel was 33.3%. There was no significant difference in PSA50 between AR-V7pos and AR-V7neg patients at C1 (Table). The PSA50 to enzalutamide was 79.3%. Similarly, there was no significant difference in PSA50 between AR-V7pos and AR-V7neg at C2 (Table). The median PFS to docetaxel and enzalutamide were 6.0 mo and 15.0 mo, respectively. There was no significant difference in PFS to docetaxel between AR-V7pos and AR-V7neg patients at C1. PFS on enzalutamide was 9.0 mo for AR-V7pos and 20.0 mo for AR-V7neg patients at C2, but the difference was not statistically significant (Table). The median PFS to the sequential treatment and OS were 23.0 mo and 30.0 mo, respectively. AR-V7pos patients at C1 had shorter PFS to sequential treatment and shorter OS (Table). Conclusions: AR-V7 expression was not associated with response to docetaxel and enzalutamide but with shorter PFS and OS to sequential treatment. AR-V7 expression may be considered a prognostic, but not predictive, biomarker in mCRPC patients. Clinical trial information: NCT03700099 . AR-V7 status at C1 AR-V7 pos AR-V7 neg OR/HR (IC95%) p-value PSA50 to Docetaxel 33.3% 35.3% OR 1.90 (0.23-5.20) >0.999 * PFS on Docetaxel 5.0 mo 6.0 mo HR 1.73 (0.80-3.73) 0.164 # PFS on Doce + Enza 13.0 mo 28.0 mo HR 2.74 (1.16-6.50) 0.022 # OS 20.0 mo 41.0 mo HR 3.28 (1.30-8.27) 0.012 # AR-V7 status at C2 AR-V7 pos AR-V7 neg OR/HR (IC95%) p-value PSA50 to Enzalutamide 76.9% 80% OR 1.20 (0.20-7.31) >0.999 * PFS on Enzalutamide 9.0 mo 20.0 mo HR 1.95 (0.82-4.64) 0.131 # OR=odds ratio, HR=hazard ratio; * Fisher's exact test; # Kaplan Meier and Log-rank.
The impact of micropapillary histology and clinical staging on overall survival in bladder cancer: A retrospective analysis.
744 Background: Micropapillary variant bladder cancer (MPC) is a rare subtype of urothelial carcinoma, representing 0.01–2.2% of cases, with a higher stage at diagnosis and increased metastatic potential. The prognostic role of MPC remains uncertain, and previous studies have been limited by small cohort sizes, with only a few larges studies. This study analyzed the prognostic impact of MPC on clinical stage and survival outcomes in the largest single-institution cohort of patients with MPC who underwent radical cystectomy (RC). Methods: This retrospective study included 130 patients who underwent RC at Memorial Sloan Kettering Cancer Center for MPC between June 21, 1995, and April 14, 2023. Data included demographic, histologic, and clinical variables, as well as overall survival (OS) outcomes. Cystectomy specimens were reviewed by genitourinary pathologists to determine the proportion of the MPC component (MPC%) in each tumor. For OS comparison, a separate cohort of 430 patients with urothelial carcinoma not otherwise specified (UC NOS) who also underwent RC was used. Patients with MPC were further stratified by stage at diagnostic transurethral resection of bladder tumor (TURBT) as either non-muscle-invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC). Additional stratifications included MPC% ( < 50% vs. ≥50%, < 20% vs. > 80%) and receipt of neoadjuvant chemotherapy (NAC). Results: MPC was associated with a significantly shorter OS compared to UC NOS patients (p = 0.011). The MPC cohort had a mean OS of 83.8 months (95% CI: 62.2–105.4) and a median OS of 36.8 months (95% CI: 22.3–51.3), whereas the UC NOS cohort had a mean OS of 72.1 months (95% CI: 66.6–77.6) and a median OS of 84.4 months (95% CI: 64.5–104.2). Within the MPC cohort, patients with MIBC at initial TURBT had significantly worse OS compared to those with NMIBC (p = 0.0005). MPC% did not impact OS, with no differences between patients with < 50% versus ≥50% MPC (p = 0.59) or < 20% versus > 80% MPC (p = 0.57). Additionally, NAC did not affect OS within the MPC cohort (p = 0.055). N stage at cystectomy (N0 vs. N1+) was also not predictive of OS (p = 0.16). Conclusions: The presence of MPC, regardless of its proportion or the use of NAC, predicts poor outcomes. Clinical stage—particularly the presence of muscle invasion—remains the key predictor of survival. These findings emphasize the importance of clinical staging in guiding treatment decisions and prognostic assessments in the management of this disease.
Incidence and mortality trends in genitourinary cancer in Southeast Asia from 1990-2021.
619 Background: The global burden of genitourinary (GU) cancers has been increasing due to aging populations and advancements in technology. However, little is known about the burden of GU cancers specific to Southeast Asia (SEA), a diverse region of over 690 million people. This study presents the most updated trends in incidence and mortality of the bladder, kidney, prostate, and testicle cancers across SEA from 1990 to 2021. Methods: Data were extracted from the Global Burden of Disease (GBD) 2021 database to analyze the incidence, deaths, and age-standardized rates (ASR) by sex and age for four major GU cancers in Brunei, Cambodia, Timor-Leste, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand, and Vietnam from 1990 to 2021. Results: From 1990 to 2021, SEA countries had an increase in overall GU cancer incidence (16,947 to 74,556) and mortality (20,500 to 61,113) for all ages. Bladder cancer showed the greatest rise in incidence (4,334 to 15,783) and deaths (8,586 to 24,375) for both sexes, while prostate cancer had the largest absolute increase in male incidence (8,431 to 42,362) and mortality (6,850 to 23,764). For bladder cancer, Thailand had the highest ASIR in 2021 for males, and Brunei for females. From 1990 to 2021, ASIR rose in Vietnam but decreased in Singapore for males, while rising in Malaysia for females. The highest ASMR in 2021 was in Malaysia for males and Brunei for females. From 1990 to 2021, ASMR declined in Singapore for males and in Singapore, Thailand, and Myanmar for females. For kidney cancer, Brunei had the highest ASIR and ASMR in 2021 for both sexes. From 1990 to 2021, ASIR rose in all countries except Timor-Leste, Myanmar, and Laos for males, and increased in Malaysia, Philippines, Indonesia, Singapore, Thailand, and Vietnam for females. ASMR rose in Indonesia, Thailand, Vietnam, and Philippines in males, and in Indonesia and Vietnam for females. For prostate cancer, Singapore had the highest ASIR in 2021, with ASIR increasing in all countries except Laos from 1990 to 2021. ASMR was highest in the Philippines in 2021. From 1990 to 2021, ASMR rose in Cambodia and Indonesia. For testicular cancer, Singapore had the highest ASIR in 2021. From 1990 to 2021, ASIR rose in all countries but Brunei and Philippines. ASMR was highest in Malaysia in 2021 and remained stable throughout the region from 1990 to 2021. Conclusions: The burden of GU cancers in SEA has significantly increased from 1990 to 2021, with bladder and prostate cancers showing the largest rises in incidence and deaths. Brunei consistently exhibited the highest ASIR and ASMR for kidney and bladder cancers. For prostate and testicular cancer, Singapore had the highest ASIR while ASMR was highest in the Philippines for prostate and Malaysia for testicular cancer. These findings highlight the urgent need for enhanced resource allocation and targeted interventions to address the growing GU cancer burden and disparities in the region.
Gaps, challenges and opportunities towards achieving the 95-95-95 targets in Cameroon: A systematic review and meta-analysis protocol
Background Given HIV elimination by 2030, the World Health Organization and the United Nations’ Programme on HIV/AIDS (UNAIDS) have set three programmatic goals that all countries should have achieved before 2025; 95% of people living with HIV should know their status (target-1); 95% of people who know their status should be linked to treatment (target-2); and 95% of people on treatment should achieve viral load suppression (i.e. VL<1000 copies/ml; target-3). Despite considerable global progress over the past decade, many low-middle-income countries are still below the expected targets. This review protocol aims to provide a standardized document for in-depth analysis of the strengths, weaknesses, opportunities and threats (SWOT) towards achieving these programmatic targets in Cameroon. Methods This systematic review will include randomized and non-randomized trials, cohorts, case-controls, cross-sectional studies, case reports and governmental notices addressing the achievements, the gaps, the challenges and the opportunities towards the 95-95-95 targets in Cameroon. The search will consider studies from 2017 to 2024, retrieved from PubMed/MEDLINE, Cochrane Central Register of Controlled Trials, Google Scholar, online African journals, and Cumulative Index to Nursing and Allied Health Literature. We will include studies reporting HIV diagnosis, HIV link to treatment or HIV viral suppression in Cameroon. Results will be stratified according to time, age-group (adults’ vs adolescents/children) and geographic locations. Primary outcomes will be “estimates on 95-95-95 programmatic goals at the national level”. Secondary outcomes will consist of the SWOT analysis towards achieving these programmatic targets. A random-effects model will be used to calculate pooled prevalence if data permits. Conclusions This systematic review and meta-analysis protocol will guide global estimation on the achievement of the 95-95-95 targets as well as the stakes and challenges within the Cameroonian setting. Final evidence from the systematic review will allow identification of the gaps and measures to be taken to fasten our move towards the 95-95-95 in Cameroon by 2025. Systematic review registration Systematic review registration: CRD42024502755.
Bioinformatics Analysis of coagulation-related genes in lung adenocarcinoma: unveiling prognostic indicators and treatment pathways
Clinical outcomes of lutetium-177-vipivotide tetraxetan in men with metastatic castration-resistant prostate cancer at a single academic center.
84 Background: Lutetium-177-vipivotide tetraxetan ( 177 Lu) was approved in 2022 for PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with prior androgen receptor signaling inhibition (ARSI) and a taxane. The impact of 177 Lu in a non-trial setting is limited. Methods: We retrospectively reviewed records of mCRPC pts who received ≥1 dose of 177 Lu at The Ohio State University from 3/2022-3/2024. Demographics, tumor histology, metastasis sites (mets), treatment (Tx) history, standardized uptake value max (SUVm), and prostate-specific antigen (PSA), at baseline (BL) and post-Tx were collected. SUVm was defined as the highest SUV from a single lesion. Outcomes were PSA response, PSA50, radiographic progression-free (rPFS) by PCWG3, and overall survival (OS). Descriptive statistics, Mann-Whitney, Chi-square, and Cox regression model were used to assess impact. Results: A total of 152 pts were included with a median follow-up of 9 months (0.1-23 m). The median age was 70 years (46-92 y), with 39% having de novo metastatic disease, and 61% had Gleason grade group ≥4. The common mets were bone (91%), lymph node (68%), and visceral (34% with 17% liver and 8% lung). The majority received prior taxanes and ARSI, and 20% radium-223. The median lines of prior Tx was 5.The median BL PSA was 56.3 ng/mL, and the median BL SUVm was 30.4. Post-Tx, 64% showed a PSA response, and 46% achieved PSA50. Among the pts with available imaging, 17% had partial response, 12% stable disease, and 48% disease progression.Tx was discontinued in 62% for:radiographic progression (66%), PSA-only progression (7%), clinical decline (24%), and toxicity (3%). At the data cutoff, mortality was 50%. Median PFS and OS was 6.7 m, and 12.2 m respectively. BL SUVm was associated with improved PSA50 (p=0.01), rPFS (p<0.01), and OS (p=0.01), and liver mets associated with worse OS (p<0.01). Conclusions: In this retrospective study of 177 Lu, we see similar PSA and PSA50 responses to reported trials. However, PFS was shorter, and mortality was higher, likely related to the use of 177 Lu in heavily treated pts with few remaining options. Optimizing biomarkers to predict Tx benefit and resistance are needed.
<i>g</i> -Rate–based machine learning model to predict overall survival (OS) in patients with metastatic prostate cancer (mPC) while on treatment.
242 Background: Dynamic biomarkers to predict OS while a pt is on treatment are unavailable in mPC. We have developed g -rate method which can estimate tumor growth ( g ) and decay ( d ) rates using PSA values. This has been validated to show a robust inverse correlation with OS using 13 clinical trials and real-world data from the US Veterans. We now explore the g -rate method in developing a multimodal machine learning (ML/AI) tool to serve as a dynamic biomarker predicting OS while a pt is on treatment. Methods: We have created a comprehensive VA database with more than 20,000 pts to assess drug efficacy in mPC. g and d rates are calculated using PSA values while on treatment via the TUMGr package for R. All available variables such as age at the start of treatment, race, treatment setting (rural vs urban), gleason score, charleson comorbidity index (CCI), hormone sensitivity, line of treatment, serial PSA, and g -rate while on treatment. The histogram-based gradient boosting tree ML algorithm is used to build the classifier. This algorithm is optimized to handle large data (records > 10,000). Sample reweighting is used to account for data imbalance by adjusting weights inversely proportional to class frequencies in the training data. Permutation importance is used to assess the significance of features in the resulting model. A binary classifier is used to predict the survival status. Shapley additive explanations (SHAP) were used to evaluate the contribution of individual features. Results: We utilized data from 25641 treatment records from 22958 unique pts; 20475 records were used for training and 5166 were used for testing ML algorithm. We identified 16 features, including demographic, CCI, baseline PSA, baseline CBC, and PSA-based g-rate for the model. The resulting model yielded an accuracy of 77%, a precision of 89.7%, a sensitivity/recall of 79%, a specificity of 73%, and an F1-score of 84%. The area under the receiver operating characteristic (ROC) curve (AUC) was 0.83. The classification results were statistically significant (p<10 -6 ).The mean absolute SHAP values revealed that starting PSA and g -rate were 2 most influential features in predicting pt survival. The model showed concordant results amongst White, Black, Hawaiian, and American Indian races, but not for Asian pts (Table). Conclusions: g -rate-based ML/AI model can accurately, consistently and reliably predict pt survival while being treated for mPC across different races as soon as 3 months once the g -rate is calculated after starting treatment. Future incorporation of this model into clinical trials may identify opportunities for early intervention for those with poor prognoses. Race Records Accuracy AUC score Precision White 3520 0.78 0.83 0.9 Black 1387 0.76 0.83 0.9 Native Hawaiian 44 0.80 0.96 1 American Indian 27 0.85 0.93 0.9 Asian 20 0.65 0.69 0.7 Unknown 168 0.77 0.86 0.9 All 5166 0.77 0.83 0.9
Vasculo-immune modulatory effects of anti-VEGF therapy in metastatic clear cell renal cell carcinoma: The A-PREDICT trial.
572 Background: Anti-vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors and checkpoint inhibitors (CPI) a standard-of-care treatment for clear cell renal cell carcinoma (ccRCC). We investigated the biology underpinning benefit of anti-VEGFR TKI in the phase II A-PREDICT trial (NCT01693822), evaluating pre- and post-treatment, fresh multiregion tumour biopsies in patients with metastatic ccRCC treated with first-line axitinib. Methods: We analysed 123 tumour samples from 52 patients, 28 with paired pre/post-treatment samples. Post-treatment samples included week-9, nephrectomy, and on-progression timepoints. ‘Responders’ had progression-free survival (PFS) ≥6 months (n=35), ‘non-responders’ with PFS <6 months (n=17). We applied a custom Nanostring panel for gene expression analysis and multiplex immunofluorescence (mIF) for orthogonal validation. Wilcoxin test was used to analyze paired observations. Results: At baseline, angiogenesis scores were similar between responders and non-responders (p=0.22). Post-treatment, the angiogenesis, vascular sprouting, and endothelial cell proliferation signature scores were significantly decreased (p=0.023, 0.0034, & 0.0082, respectively) in all patients, suggesting suppression of angiogenesis and neovascularisation irrespective of clinical outcomes. mIF in 3 patients (with PFS of 3, 5.6, & 100 months) confirms widespread intratumoral vessel depletion. Immune deconvolution analysis shows total levels of T cells and CD8 + T cells were similar pre- and post-treatment, suggesting axitinib did not enhance immune cell trafficking. Rather, axitinib promoted increased levels of exhausted CD8 + T cells post-treatment (p=0.01). M2 tumour-associated macrophages increased post-treatment in responders (p=0.033) but not in non-responders (p=0.44). A minority of patients had durable (>2 years) responses to axitinib (n=7/65, 6 with tissue for analysis). In these patients, we found higher levels of pre-treatment intratumoral cytotoxic immune cells (p=0.041) and NK cells (p=0.015) compared to patients with primary resistant disease. Conclusions: Axitinib suppressed angiogenesis and neovascularisation leading to intratumoral vessel depletion, and therapy response associates with features of an immunosuppressive TME. Baseline endogenous immune priming appears critical for durable response to anti-VEGF therapy. These data are relevant to understanding the clinical efficacy of combined anti-VEGF and CPI regimens. Clinical trial information: NCT01693822 .
The role of conventional imaging and piflufolastat F18 in newly diagnosed and recurrent prostate cancer patients: Preliminary observations from the PYLARIFY Registry.
41 Background: Next generation imaging modalities for the diagnosis and characterization of prostate cancer have seen increased utilization in the past several years. PSMA-PET imaging has seen particular promise as a more accurate modality compared to conventional (CT, skeletal scintigraphy and PET) imaging. Use of PSMA imaging can significantly improve how prostate cancer is staged and thus enhance the clinicians’ confidence in therapeutic decision making. Methods: The PYLARIFY Registry (NCT 05712473), conducted under SoNaR, a Specialty Networks Registry, is a US-based multi-center prospective 5 year observational study following patients receiving standard of care piflufolastat F18 imaging as part of their prostate cancer management. The registry includes newly diagnosed patients who have not yet initiated any treatment (Cohort 1) and patients with biochemical recurrence (Cohort 2). Demographics, all baseline imaging procedures and the frequency of each type of imaging for the first 100 enrolled patients were analyzed. We also explored time-to-PSMA for newly diagnosed patients who received conventional imaging as part of their staging assessment. The clinician confidence ratings that the piflufolastat F18 imaging had on treatment decision making were also evaluated. Results: The first 100 patients had a mean age of 71.0 (SD 9.1) and 80% had a Gleason Grade group of 2 or higher. At least 1 conventional imaging procedure prior to the piflufolastat F18 PET scan was performed on 10% of patients in Cohort 1 and 77% in Cohort 2. For Cohort 1 patients, piflufolastat F18 scans were preceded by a total of 4 imaging procedures, with an average of 1 conventional imaging procedure per patient prior to their piflufolastat F18 scan. Cohort 2 patients had a total of 95 imaging procedures with an average of 1.58 conventional imaging procedures per patient prior to their piflufolastat F18 scan. The 3 most utilized conventional imaging modalities in both cohorts of patients that received conventional imaging prior to piflufolastat F18 scans were CT (80%), and skeletal scintigraphy (72%) and PET (26%). The median difference in diagnostic journey length between Cohort 1 newly diagnosed patients having conventional imaging and those having only piflufolastat F18 was 28 additional days. Across both cohorts, clinicians rated improvement in treatment planning confidence following 96% of piflufolastat F18 scans. Conclusions: Piflufolastat F18 provides a high degree of confidence for prostate cancer patient management. A growing number of patients are being managed with piflufolastat F18 scans only. Many patients however still undergo lengthy and resource-intensive conventional imaging procedures prior to their piflufolastat F18 scan.
In vitro antibiofilm efficacy of ertapenem, tobramycin, and moxifloxacin against biofilms grown in a glass bead or CDC Biofilm Reactor®
Laboratory grown biofilms are used to simulate bacterial growth in diverse environmental conditions and screen the effectiveness of anti-biofilm therapies. Recently, we developed a glass bead biofilm reactor that utilizes low broth volume to provide high-throughput biofilm growth for testing and translation across the research continuum (e.g., benchtop assays to preclinical models). Bioburden per mm2 surface area of Staphylococcus aureus and Pseudomonas aeruginosa biofilms were comparable on beads and CDC Biofilm Reactor® coupons. In this study, we hypothesized that biofilms grown on beads would be more susceptible to ertapenem, moxifloxacin, and tobramycin than those grown on coupons. Results indicated a significant reduction in S. aureus bioburden on glass beads compared to glass coupons following treatment with ertapenem (p = 0.005) and tobramycin (p = 0.014). P. aeruginosa biofilms had smaller differences in antibiotic response between the two systems. There was a significantly greater reduction in bead P. aeruginosa biofilm than coupon when treated with tobramycin (p = 0.035). This work offered insight into how the bead biofilm reactor could be used as a tool for antibiotic screening and translation across the continuum of in vitro to in vivo systems that support development of antimicrobial technology.
Development of a wireless electroretinogram recording system
Abstract A novel device consisting of amplifiers, an analogue-digital converter, offset correction units, and a microcontroller with Bluetooth wireless functionality was fabricated. Electroretinography (ERG) recordings were captured in dark-adapted and light-adapted full-field flash stimulations in an anaesthetised animal model using the novel wireless system. Recordings were repeated using a standard ERG recording setup of the Espion E3 system for comparison. The electroretinogram signal a-wave and b-wave amplitudes, peak times, signal offset, potential drift, and power line noise were compared between the recording setups. Signals from the novel system were found to have similar waveforms to those recorded from the standard ERG setup. There were no significant differences in the a-wave amplitudes ( P > 0.43), a-wave peak times ( P > 0.61) and b-wave peak times ( P > 0.55). The offset potential drift when using the novel system was significantly smaller than the reference system ( P < 0.02). The novel system also showed stronger resilience against powerline noise interference, as evidenced by a statistically significant performance increase during recordings with substantial noise interference ( P < 0.01). The on-source signal processing and wireless transmission can improve the quality of recorded ERG signals. Our study demonstrates a proof of concept for performing wireless ERG recordings, which enhance the performance by reducing noise and potential drift in the recorded signals.
Management of metastatic castration-resistant prostate cancer (mCRPC) at the Veterans Affairs Healthcare System (VAHCS): A real-world assessment of patient characteristics and treatment across lines of therapy.
60 Background: With the emergence of several newly approved therapies for mCRPC, data on the optimal treatment sequence are limited. The aim of this study is to understand the treatment patterns of mCRPC patients who received at least one androgen receptor pathway inhibitor (ARPI) or taxane at the VAHCS, an equal-access healthcare system. Methods: This is a retrospective, observational study utilizing VAHCS claims data from patients diagnosed with mCRPC between January 1, 2018 and February 29, 2024 nationwide. Patients with mCRPC who received first-line (1L) therapy of ARPI (abiraterone, enzalutamide, darolutamide, or apalutamide; [ARPI cohort]) or a taxane (docetaxel or cabazitaxel; [taxane cohort]) were included; 1L therapy was defined as the first prescription for ARPI or taxane after prostate cancer diagnosis. Thus, though the 1L treatment could have been for metastatic castration-sensitive prostate cancer or mCRPC, all patients ultimately progressed to mCRPC. Patients who received radiation within 6 months or any other chemotherapy prior to 1L therapy, or who were diagnosed with any other cancers (excluding non-melanoma skin cancer) prior to mCRPC were excluded. Results: In total, 2982 patients with mCRPC who met the inclusion criteria were identified, which included a large cohort of African American patients (25%). Although most patients received an ARPI in the 1L (2828 patients, 95%), 154 patients (5%) received 1L taxane. Patients in the ARPI cohort were significantly older than those in the taxane cohort (median 74 vs 68 years; p<0.001). Patients in the ARPI cohort received mainly 1L abiraterone or enzalutamide with a similar frequency (both 48%), and docetaxel was the most common treatment for patients who had received 1L taxane (97%). Overall, 1223 patients (41% of all patients) received second-line (2L) therapy. Taxanes were more frequently used in 2L treatment (16%) compared with 1L; however ARPI, especially abiraterone (27%) and enzalutamide (42%), remained the most frequent choices for 2L treatment. Back-to-back ARPI use in 1L and 2L was the most common treatment sequence, with 74% of patients who received 2L abiraterone having been treated with 1L enzalutamide, and 87% of patients who received 2L enzalutamide having been treated with 1L abiraterone. Few patients (11% of all patients) received third-line (3L) treatments. Conclusions: In the VA equal-access healthcare system, back-to-back ARPIs remained the most common treatment sequence for the management of patients with mCRPC with few patients receiving 3L treatment. Further research is planned to investigate clinical outcomes, adverse events, and healthcare resources utilization associated with these treatment sequences to hopefully identify an optimal mCRPC management.
THERATEST: A multi-centre observational cohort feasibility study of de-escalation therapies for stage II seminoma.
TPS651 Background: Standard of care (SOC) for stage II seminoma involves primary orchidectomy with combination chemotherapy or external beam radiotherapy, and yield high survival rates but with significant toxicities. Three cycles of Carboplatin AUC10 or robotic retroperitoneal lymph node dissection (rRPLND) with or without adjuvant chemotherapy are promising de-escalation strategies to minimise treatment associated toxicities whilst maintaining oncological outcomes. However, they are not widely adopted due to a lack of comparative data in prospective clinical trials. Therapy De-escalation for Testicular Cancer (THERATEST) aims to assess the feasibility of recruitment for de-escalation strategies for stage II seminoma. Methods: Thirty participants will be recruited over 12 months and treated with either Carboplatin AUC10 or rRPLND with or without adjuvant treatments based on whether the institution offers this treatment as a de-escalation strategy. If participants decline or are not eligible, they will be offered SOC but remain within the study. Both cohorts will be followed up for 2-years. Data collection includes recruitment and retention rates, disease status, surgical outcomes, adverse events and patient-reported outcomes using validated questionnaires which are EORTC QLQ-TC26, EORTC QLQ-C30, the Brief Male Sexual Function Inventory (BMSFI) and additional enquiries on anejaculation. Results: THERATEST has recently commenced recruitment at Barts Health and the Royal Marsden Hospital NHS Trusts. Conclusions: THERATEST is the first endeavour to prospectively evaluate Carboplatin AUC10 and rRPLND as de-escalation strategies for stage II seminoma in a single study. Feasibility of recruitment and retention as well as qualitative and quantitative outcomes data will inform a large-scale multicentre trial. Clinical trial information: ISRCTN61007118 .
CONVERGE-01: Dosimetry, randomized dose optimization, dose escalation, and efficacy of ac-225 rosopatamab tetraxetan in participants with PSMA-positive castration-resistant prostate cancer.
TPS289 Background: Prostate specific membrane antigen (PSMA) is a validated target in metastatic castration resistant prostate cancer (CRPC). Use of an alpha emitter as a radionuclide and a high affinity monoclonal antibody for protein targeting in PSMA-targeted radiopharmaceutical therapy (TRT) offer the promise of improved precision and potency as compared to alternative approaches. Ac-225 rosopatamab tetraxetan (CONV01-ɑ, formerly Ac-225-J591) has been evaluated for safety and efficacy in sequential investigator-initiated trials (Tagawa et al. JCO 2024, Nauseef et al . AACR 2023) with encouraging results in patients with and without prior exposure to PSMA-directed Lu-177-small molecule-based TRT. The phase II CONVERGE-01 trial is the first industry-sponsored study of CONV01-ɑ and will further advance the understanding of safety and efficacy in patients with progressive PSMA PET-positive CRPC. Methods: The study is being conducted in three parts. Part 1 (P1) is a lead-in to evaluate the biodistribution of CONV01-ɑ using In-111 rosopatamab tetraxetan. Each of these patients will then proceed to Part 2 or Part 3. Part 2 (P2) randomizes 1:1 between 45 and 60 kBq/kg in patients with CRPC without prior exposure to Lu-177-PSMA (-617 or -I&T). Part 3 (P3) is a Bayesian Optimal Interval (BOIN) design dose-escalation protocol (45, 55, and 60 kBq/kg, with optional dose expansion) for patients with metastatic CRPC and prior exposure to Lu-177-PSMA. Key study-wide inclusion criteria include PSMA PET-positive (via VISION criteria) progressive CRPC. Metastatic disease on conventional imaging (CT, MRI) is not mandated in P2 (stratification factor: conventional imaging M0 v M1). All patients will have prior exposure to at least 1 androgen receptor signaling inhibitor and have adequate performance status (ECOG 0-1) and organ function (platelets ≥150 k/uL, ANC ≥1.5 k/uL, CrCl ≥60 mL/min). Key study-wide exclusion criteria include: superscans on Tc-99 bone scintigraphy, prior platinum-based chemotherapy or PARP inhibitor use, and prior PSMA-targeted non-TRT use. Additional P2-specific exclusions are: prior chemotherapy for CPRC and radiopharmaceuticals. Treatment: CONV01-α (P2/P3) will be given in a single cycle of two fractions on days 1 and 15. Primary endpoints: biodistribution of radiolabeled CONV01-α (P1), safety and tolerability (P2, P3), determination of RP2D (P3 only), efficacy via PSA50 response (P2, P3 at RP2D). Secondary endpoints: biodistribution and pharmacokinetic profile (P2, P3), characterization of Ac-225 radiation dosimetry (P2), biochemical PFS (P2), PSA50 (P3, all patients treated). Exploratory endpoints include: rPFS, ORR, and DOR via RECIST v1.1 (PCWG3-modified where appropriate), genomic and imaging biomarker nomination. Enrollment began in August 2024. Clinical trial information: NCT06549465 .
Comparison of PSA-based <i>g</i> -rate and conventional PSA metrics in veterans with metastatic prostate cancer (mPC).
188 Background: While PSA is routinely used for monitoring in clinics for pts with mPC, it is not a surrogate endpoint for survival or benefit in the majority of cases for specific interventions. However, a novel tumor growth rate ( g -rate) method that can estimate tumor growth ( g ) and decay ( d ) rates using PSA values while on treatment, has the potential to serve as such. This has been validated to show a robust inverse correlation with overall survival (OS) using 13 clinical trials and real-world data from the US Veterans in mPC regardless of type of treatments. We now compare its prognostic utility to currently used PSA metrics. Methods: We have created a comprehensive database to assess drug efficacy in mPC by collecting data from the VA nationalized data warehouse using VA Informatics. Details such as age, race, serial PSA values, reason for treatment, castrate sensitive (mCSPC) or resistant (mCRPC) setting, line of therapy, and survival were collected. g and d rates are calculated using PSA values while on treatment via the TUMGr package for R. Results: We collected PSA values on 38,929 treatment records from 25,023 unique pts getting novel hormonal therapies (abiraterone, enzalutamide, darolutamide, apalutamide), chemotherapies (docetaxel, cabazitaxel) or olaparib. Of this, 17383 had achieved a nadir followed by an increase in PSA, 10738 had the last available result as their lowest, and 10808 had a PSA rise only while on treatment. Nadir-based PSA metrics, such as 50% decrease in PSA (PSA50), absolute PSA nadir, percent PSA nadir can be applied to 28,121 (72%) of records. PSA50 response rate was noted in 1780/2390 (84%) mCSPC and 16796/36539 (65%) mCRPC pts. Only 487 (20%) and 155 (6.5%) of mCSPC and 2038(5.6%) and 508 (1.4%) of mCRPC achieved PSA of 0.2 and 0.02 at 6 months(mo), respectively. For pts with PSA rise only, PSA doubling time(DT) of < 3 mo was noted in 5843 (54%). However, g -rate was calculated in 36124 (93%) of pts regardless of treatment type, treatment setting, and rise or fall in PSA while on treatment. 22,800 pts had at least 3 PSA values within the first 3 mo of starting treatment, and we could calculate either g or d values in 19,465 (85%) of pts. Linear regression testing of both log g and log percent PSA nadir revealed a robust inverse correlation with OS, with R 2 of 0.98 and 0.99, respectively. Conclusions: PSA decline with absolute 6 mo PSA < 0.2 or PSA increase with DT of < 3 mo was noted in only 26% and 54 % of pts, respectively, noting limitation of current validated PSA metrics. In contrast, we can calculate the g -rate in 93% of pts on treatments and g values can be calculated or imputed as early as 3 months. It has a robust inverse correlation with OS demonstrating its superiority over PSA kinetics alone. The g -rate method can potentially replace all current PSA-based metrics regardless of decline or increase in PSA for assessing treatment response in mPC in both research and clinical settings.
Perception of four intellectual and developmental disabilities based on search engine and news portrayal
Background For people with intellectual and developmental disabilities, other’s perceptions of them based on their condition often begin before birth and go on to impact relationships, opportunities, and self perception across the life course. Search engine results and news media, which may portray these conditions stereotypically or in poor light, are often a key source in these perceptions. Our purpose was to understand how search engine results and available news media can shape perceptions on certain intellectual and developmental disabilities. Methods We developed an online Likert-scale survey to measure differences in perceptions based off first available search engine results, images, and news headlines of four intellectual and developmental disabilities: cerebral palsy, Down syndrome, Prader-Willi syndrome, and Angelman syndrome. These four conditions were selected to compare less prevalent (Prader-Willi and Angelman) and more prevalent conditions (Down syndrome and cerebral palsy). Perception questions addressed general impression and aspects of the disability experience expected to be impacted by perception from others. We recruited via multiple social media platforms, flyers posted in the Boston area, and word of mouth to local communities and friends. Findings 229 individuals opened the survey, and 125 responses were used in analysis. Mean responses to Prader-Willi syndrome were significantly more negative than responses to cerebral palsy, Down syndrome, and Angelman syndrome across all variables. Responses to Angelman syndrome were also more negative than responses to Down syndrome. Significant differences between conditions found when treating the data as continuous were confirmed when treating the data as ordinal. Conclusion Lesser-known intellectual and developmental disabilities, such as Prader-Willi syndrome and Angelman syndrome, are subject to more negative portrayal in media, leading to more negative perception, which may impact social opportunity and quality of life. Combined with our finding that the perception of Prader-Willi syndrome follows the ideals of the medical model of disability more closely than the social model, a need for social model of disability training and education for physicians and other medical providers is clear.
Optimization of toilet bowl ventilation technology for odor control and energy efficiency enhancement in public toilet
Frequency and impact of a genome-wide homologous recombination deficiency signature (HRDsig+) on the genomic landscape of clinically advanced penile squamous cell carcinoma (CAPSCC).
824 Background: CAPSCC is a challenging disease with significant need for improvements in effective systemic therapies for patients with surgically incurable disease. Methods: 373 cases of CAPSCC underwent comprehensive genomic profiling to examine all classes of genomic alterations (GA). MSI high status, tumor mutation burden (TMB) levels, genomic ancestry and trinucleotide mutational signatures were determined from the sequencing data. HRDsig status was calculated using a broad set of genome-wide copy number features (PMID 37769224). PD-L1 was determined by IHC using the Dako 22C3 tumor proportional score (TPS) system. Results were compared using the Fisher exact system. Results: 13 (3.5%) of the CAPSCC cases featured a positive HRDsig status (HRDsig+). The PSCC HRDsig+ patients were older than the PSCC HRDsig+ patients (median ages 67 vs 62; NS). The GA/tumor frequencies were higher in the PSCC HRDsig- cases (5 v3 3; NS). Genomic ancestry distribution was similar with 68-77% of patients featuring EUR ancestry. 9.4% of PSCC HRDsig- featured AFR ancestry compared with 0% PSCC HRDsig+ (NS). MSI-high status was extremely low in both HRDsig- vs HRDsig+ PSCC groups (1.4% vs 0.0%; NS). Although the median TMB was higher in the HRDsig+ (6.3 vs 3.8; NS); the frequency of TMB > 10 mutations/Mb was similar in both groups (13.3% vs 17.7%; NS). Trinucleotide mutational signature distribution was similar in both cohorts. PD-L1 low (1-49% TPS) expression was similar in both groups and ranged from 43% to 52%. Only 1 (7.7%) of the 13 PSCC HRDsig+ cases featured a BRCA1 inactivating mutation and 0 (0%) had a BRCA2 mutation. In the HRDsig- group, 66.7%/75.0% of BRCA1 / BRCA2 mutated CAPSCC were mono-allelic likely non-driver GA respectively. Other HRD associated mutations in the PSCC HRDsig+ cases included 2 (15.4%) ATM and 1 (7.7%) PALB2 mutation. The PALB2 mutation was a bi-allelic homozygous deletion which has been linked to prolonged benefit from PARP inhibitor-based treatments. GA in both TERT (51.1% vs 0.0%; P=.009) and TP53 (53.3% vs 23.1%) were more frequent in the PSCC HRDsig- cases whereas GA in MAP2K1 (15.4% vs .0%; P=.025), KRAS (15.4% vs 1.1%); NS) and NF1 (15.4% vs 1.4%; NS) were more frequent in the PSCC HRDsig+ cases. NOTCH1 GA were similar in both groups (range 16.4% to 15.4%). There was no difference in the frequencies of HPV+ status between the 2 groups. Conclusions: With a 3.5% frequency, HRDsig+ status is a relatively uncommon biomarker in CAPSCC. However, HRDsig+ status appears to occur in PSCC in the absence of BRCA1 / 2 mutations and may include homozygous deletions in HRD-associated genes such as PALB2 that been associated with substantial benefit from PARPi regimens in other tumor types. These findings may impact the future development of PARP inhibitor-based treatment regimens for PSCC patients.